UK biotech draws Pfizer backing in £40.5M Series A for peptide-inspired drugs
27 Feb 2024
PDCPhase 1PROTACs
Curve Therapeutics has raised £40.5 million ($51.4 million) in a Series A round to advance its small cyclic peptide-based discovery platform and drug candidates, including plans for a Phase I cancer trial in 2026.
The proceeds will be used to take one of the UK biotech’s two preclinical programs into a Phase I oncology trial, with one option being a dual inhibitor of hypoxia-inducible factor isotopes, and the other an AICAR transformylase/inosine monophosphate cyclohydrolase (ATIC) dimerization inhibitor.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.